A5101833516- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Gastric Cancer Management and Outcomes
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Ferroptosis and cancer prognosis
- Immunotherapy and Immune Responses
- RNA modifications and cancer
- Pancreatic and Hepatic Oncology Research
- Cancer-related molecular mechanisms research
- Cancer Cells and Metastasis
- Hepatocellular Carcinoma Treatment and Prognosis
- Fungal Biology and Applications
- Digestive system and related health
- Immunodeficiency and Autoimmune Disorders
- Immune Cell Function and Interaction
- Gastrointestinal Tumor Research and Treatment
- Cancer therapeutics and mechanisms
- Cancer, Lipids, and Metabolism
- Plant pathogens and resistance mechanisms
- Clinical Nutrition and Gastroenterology
- Immune cells in cancer
- Nutrition and Health in Aging
Shandong Tumor Hospital
2020-2024
Hebei Medical University
2018-2024
Xingtai People's Hospital
2018-2024
Peking University Cancer Hospital
2024
Shandong First Medical University
2020-2024
Peking University
2024
Unimed Medical Institute
2020
ALK-Abelló (Germany)
2020
Abstract Treatment options for patients with relapsed extensive-stage small cell lung cancer (ES-SCLC) remain scarce. This study aims to evaluate the efficacy and safety of combining anlotinib sintilimab plus chemotherapy as a second line or later therapy ES-SCLC patients. is phase II clinical trial (ChiCTR2100049390) conducting at Shandong Cancer Hospital. Patients received least one prior systemic treatment were enrolled. The design involved combination (sintilimab, anlotinib,...
Objective Robust biomarker predicting efficacy of immunotherapy is limited. Circulating tumor DNA (ctDNA) sought to effectively monitor therapeutic response as well disease progression. This study aims investigate predictive role ctDNA short-term dynamic change (6 weeks postimmunotherapy) in a single-arm, phase 2 trial sintilimab plus docetaxel for previously treated advanced non-small cell lung cancer (NSCLC) patients. Methods A total 33 patients with NSCLC progression during or after any...
HBM4003 is a novel anti-CTLA-4 heavy chain-only antibody, designed to enhance Treg ablation and antibody-dependent cell-mediated cytotoxicity while ensuring manageable safety profile. This phase I trial investigated the safety, pharmacokinetics, immunogenicity preliminary efficacy of plus with anti-PD-1 antibody toripalimab in patients advanced solid tumors, especially focusing on melanoma.
Tissue inhibitor of metalloproteinase 1 (TIMP1) has been implicated in prostate cancer metastasis. In this study, PC-3M-2B4 cells with TIMP1 knockdown (PC-3M-2B4-shTIMP1) or over-expression (PC-3M-2B4-TIMP1) were generated and an inverse correlation was found between expression cell migration invasion which confirmed vitro vivo. Differential accompanied by variations the ferroptosis-related proteins, glutathione peroxidase 4 (GPX4), transferrin receptor (TFRC), (TF), glutamine cysteine...
Apatinib has been proved to be effective and well tolerated among patients in phase II III studies. Here, we evaluated the safety effectiveness of apatinib advanced gastric cancer a real-world setting.This study enrolled who had progressed or relapsed despite systemic chemotherapy. The primary outcome was secondary outcomes included overall survival (OS) progression-free (PFS).A total 337 were included. In total, 62 (18.4%), 102 (30.3%), 173 (51.3%) received first, second, third higher line...
Gastric cancer (GC) is a leading cause of cancer-related morbidity and mortality globally. This meta-analysis was conducted to assess the impact nutritional interventions on clinical outcomes in GC patients.
The involvement of immune dysfunction in the pathogenesis lung cancer has been extensively studied. However, potential molecular mechanisms through which tumor response affects drug resistance are still unclear. Accordingly, this study, we evaluated deviations cell landscape among patients with different stages adenocarcinoma to identify key microRNAs and their targets associated patient outcomes. CIBERSORT was used for estimating proportions cells various tissues. Significantly adaptive...
Abstract Introduction: The approval of immune checkpoint inhibitor (ICPI) for hepatocellular cancer (HCC) has changed the landscape HCC treatment, which is second most common and lethal malignancy in China. Several genomic features associated with ICPI efficacy various types cancers been reported as potential predictive biomarkers. application comprehensive profiling (CGP) on might be useful identifying responders or avoiding adverse effect. Experimental procedure: Comprehensive 107 advanced...
Abstract Rationale: The anaplastic lymphoma kinase (ALK) fusion has been identified to be a driver gene in lung cancer, and serves as important diagnostic therapeutic targets. Owing the advanced sequencing technologies, new partner genes of ALK have constantly detected. Patient concerns: A 55-year-old Chinese woman went our hospital because cough expectoration for 1 year. patient had no fever, chest pain hemoptysis. Diagnoses: She was diagnosed with adenocarcinoma. Because she operational...
Indoleamine 2,3-dioxygenase 1 (IDO1) catalyzes the first step of tryptophan catabolism in kynurenine (Kyn) pathway. IDO1 downregulates natural killer cell receptors, and by mechanism, tumor cells escape immune surveillance.IDO1 protein mRNA were assessed immunohistochemistry, immunoblotting, PCR 68 resected lung adenocarcinomas at stages I-III as well adjacent normal tissues. Infiltration CD3, CD8, CD4 lymphocytes tissues was immunohistochemical staining.IDO1 detected various adenocarcinoma...
The poor survival rate of small cell lung cancer (SCLC) is mainly related to the condition that patients with SCLC often have good responses first-line chemotherapy initially, but later on, most these relapse rapidly due resistance further treatment. In this study, we attempted analyze whole-exome sequencing data based on largest sample size date, develop a classifier predict whether patient will be chemorefractory or chemosensitive and explicate risk recurrence affects prognosis patients....
Abstract Introduction: The proofreading 3'-5' exonuclease activities of DNA polymerase-ϵ (POLE) and δ (POLD1) are critical for preventing mutations. POLE POLD1 mutations can lead to high tumor mutational burdens (TMB), predict responsiveness immune checkpoint inhibitors (ICPI) in the absence microsatellite instability (MSI). We therefore analyzed genomic alterations Chinese colorectal cancer (CRC) patients by comprehensive genome profiling (CGP). Method: A cohort 123 CRC (pts) comprising 76...
e13515 Background: Pancreatic adenocarcinoma (PAC) remains one of the most deadly diseases with short-lived treatment responses. KRAS is dominant driver gene in PAC, contributing to approximately 90% PAC. Studies had revealed molecular profiles Western population, but mutational signatures Chinese PAC need be further investigated. Methods: FFPE tumor and matched blood samples 81 patients (pts) including 52 males (64.2%) 29 females (35.8%) a median age 60 (range: 37-86) were collected for...
Abstract Background:Amplification and/or overexpression of human epidermal growth factor receptor-2 (HER2, also known as ERBB2) were present in 6.1-23.0% gastric cancer. In breast cancer, amplification and the HER2 are associated with poor prognosis. Meanwhile, MSI-H patients have an improved prognosis However, little is about association these two indicators Method:260 tumor tissues matched normal from cancer included this study to reveal microsatellite status distribution Chinese using...